Clinical Trials in Sherman Oaks, California
19 recruiting
Showing 1–19 of 19 trials
Recruiting
Phase 2
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
Major Depressive Disorder
AbbVie195 enrolled31 locationsNCT07276997
Recruiting
Phase 3
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC641 enrolled193 locationsNCT06319820
Recruiting
Phase 3
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Alzheimers Disease
Hoffmann-La Roche800 enrolled135 locationsNCT07170150
Recruiting
Phase 2
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
Bipolar I DisorderBipolar II Disorder
AbbVie195 enrolled22 locationsNCT06696755
Recruiting
Phase 3
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
Depressive Disorder, Major
Janssen Research & Development, LLC752 enrolled200 locationsNCT06559306
Recruiting
Phase 3
Study to Assess the Safety and Effectiveness of NMRA-335140-501
Major Depressive Disorder
Neumora Therapeutics, Inc.1,000 enrolled177 locationsNCT06029439
Recruiting
Phase 3
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Alzheimers Disease
Hoffmann-La Roche13,000 enrolled207 locationsNCT07177352
Recruiting
Phase 3
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Schizophrenia
Neurocrine Biosciences284 enrolled21 locationsNCT06963034
Recruiting
Phase 2
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
Schizophrenia
MapLight Therapeutics300 enrolled25 locationsNCT07038876
Recruiting
Phase 3
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics800 enrolled412 locationsNCT05980949
Recruiting
Phase 3
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
Heart Failure
AstraZeneca11,300 enrolled917 locationsNCT06677060
Recruiting
Phase 3
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc.522 enrolled60 locationsNCT06894212
Recruiting
Phase 2
A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder
Social Anxiety Disorder
VistaGen Therapeutics, Inc.60 enrolled9 locationsNCT06809179
Recruiting
Phase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
Alzheimer DiseaseAgitation
Celgene120 enrolled52 locationsNCT06808984
Recruiting
Phase 2
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
Generalized Anxiety Disorder
Intra-Cellular Therapies, Inc.570 enrolled60 locationsNCT06701903
Recruiting
Phase 3
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
Major Depressive Disorder
Xenon Pharmaceuticals Inc.450 enrolled30 locationsNCT07076407
Recruiting
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
Celiac DiseaseMultiple SclerosisAnkylosing Spondylitis+6 more
TScan Therapeutics, Inc.300 enrolled12 locationsNCT06587828
Recruiting
Phase 1Phase 2
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
Non Muscle Invasive Bladder Cancer
ImmunityBio, Inc.596 enrolled80 locationsNCT02138734
Recruiting
Phase 3
P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
AnxietySocial Anxiety DisorderADHD+1 more
Otsuka Pharmaceutical Development & Commercialization, Inc.308 enrolled47 locationsNCT06973577